Radar›Companies›Top Medicinal Chemicals And Botanical Products Stocks in USA
United States medicinal chemicals and botanical products industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Top Medicinal Chemicals And Botanical Products Stocks in USA

Five U.S.-listed medicinal chemicals and botanical products names, read through one evidence stack: market path, official filing history, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderAWH · 40
Strongest available pathBiote · -83.1%
Widest latest marginBiote · 14.1%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1AAWH · OTC

AWH

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 2014Cambridge, Massachusetts$80.3M market cap
View full Companies Radar profile
40Cautious
Snapshot price$0.40as of page date
Monthly-close return-96.0%five-year window
FY2022 revenue$0.41BAscend Wellness Holdings, Inc.
Net margin-19.9%FY2022
Prism attention48.7%share across these five
Filing track recordRevenue, USD billions
+22.1%
$0$0.1B$0.3B$0.4BFY2021: $0.332BFY2022: $0.406B20212022
FY2021–FY2022 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.1%
52-week position7% through range
$0.34$1.20
News mentions1.5K
Community mentions0partial coverage
U.S.-scope patents533
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position12/100
Capital-event signal71/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 2 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2BTMD · Nasdaq

Biote

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 2011Irving$53.2M market cap
View full Companies Radar profile
38Cautious
Snapshot price$1.57as of page date
Monthly-close return-83.1%five-year window
FY2025 revenue$0.19Bbiote Corp.
Net margin14.1%FY2025
P/E snapshot11.2xone ratio, not a verdict
Prism attention8.4%share across these five
Filing track recordRevenue, USD billions
+16.5%
$0$0.1B$0.1B$0.2BFY2022: $0.165BFY2023: $0.185BFY2024: $0.197BFY2025: $0.192B2022202320242025
FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.2%
52-week position13% through range
$1.27$3.62
News mentions254
Community mentions0partial coverage
U.S.-scope patents30524
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal65/100
Management stability90/100
Market position5/100
Capital-event signal5/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3USNA · NYSE

USANA Health Sciences

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 1992Salt Lake City, Utah$259.4M market cap
View full Companies Radar profile
36Cautious
Snapshot price$14.04as of page date
Monthly-close return-85.5%five-year window
FY2025 revenue$0.93BUSANA HEALTH SCIENCES INC
Net margin1.2%FY2025
P/E snapshot7.9xone ratio, not a verdict
Prism attention24.4%share across these five
Filing track recordRevenue, USD billions
-12.8%
$0$0.4B$0.8B$1.2BFY2019: $1.061BFY2020: $1.135BFY2022: $1.186BFY2023: $0.855BFY2025: $0.925B20192020202220232025
FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2019 · CAGR -3.4%
52-week position7% through range
$12.57$32.29
News mentions738
Community mentions0partial coverage
U.S.-scope patents9
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal50/100
Management stability90/100
Market position8/100
Capital-event signal10/100
Innovation pulse7/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4MRMD · OTCQX

MariMed Inc

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 2011Norwood, Massachusetts$33.5M market cap
View full Companies Radar profile
35Cautious
Snapshot price$0.08as of page date
Monthly-close return-90.7%five-year window
FY2025 revenue$0.16BMARIMED INC.
Net margin-9.1%FY2025
Prism attention10.5%share across these five
Filing track recordRevenue, USD billions
+31.6%
$0$0.1B$0.1B$0.2BFY2021: $0.121BFY2022: $0.134BFY2023: $0.149BFY2024: $0.158BFY2025: $0.160B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 7.1%
52-week position12% through range
$0.06$0.23
News mentions317
Community mentions4partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal55/100
Management stability90/100
Market position0/100
Capital-event signal10/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5NAII · Nasdaq

Natural Alternatives International

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 1980San Marcos, California$13.6M market cap
View full Companies Radar profile
34Cautious
Snapshot price$2.16as of page date
Monthly-close return-85.5%five-year window
FY2025 revenue$0.13BNATURAL ALTERNATIVES INTERNATIONAL INC
Net margin-10.5%FY2025
Prism attention8.0%share across these five
Filing track recordRevenue, USD billions
-27.3%
$0$0.1B$0.1B$0.2BFY2021: $0.179BFY2022: $0.171BFY2023: $0.154BFY2024: $0.114BFY2025: $0.130B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -7.6%
52-week position5% through range
$2.00$4.96
News mentions241
Community mentions0partial coverage
U.S.-scope patents28
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal47/100
Management stability90/100
Market position0/100
Capital-event signal20/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Biote
-83.1%
USANA Health Sciences
-85.5%
Natural Alternatives International
-85.5%
MariMed Inc
-90.7%
AWH
-96.0%

Latest revenue

USD billions, official filing scope shown on each company card.

USANA Health Sciences
$0.93B
AWH
$0.41B
Biote
$0.19B
MariMed Inc
$0.16B
Natural Alternatives International
$0.13B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Biote
14.1%
USANA Health Sciences
1.2%
MariMed Inc
-9.1%
Natural Alternatives International
-10.5%
AWH
-19.9%

Prism news attention

Normalized share across these five names; attention is not quality.

AWH
48.7%
USANA Health Sciences
24.4%
MariMed Inc
10.5%
Biote
8.4%
Natural Alternatives International
8.0%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized medicinal chemicals and botanical products news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

AWH leads the conversation

It holds 48.7% of measured medicinal chemicals and botanical products news attention and also carries the basket's largest revenue base at $0.41B.

Price path

Biote leads the available price paths

Its monthly-close return is -83.1% for the five-year window. At the other end, AWH is -96.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Biote has the widest latest margin

Its FY2025 net margin is 14.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

USANA Health Sciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 7.9x while its five-year window price return is -85.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · AAWH

AWH

1,469available Prism news records

Prism top themes

Earnings & financial performance
73
Price action & investor response
28
Leadership & governance
13
Legal, arbitration & regulatory
8
Capital allocation & transactions
2

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-0.7%148 latest 12m vs 149 prior 12m
2024-02: 12 mentions2024-03: 11 mentions2024-04: 8 mentions2024-05: 17 mentions2024-06: 14 mentions2024-07: 22 mentions2024-08: 20 mentions2024-09: 7 mentions2024-10: 7 mentions2024-11: 9 mentions2024-12: 13 mentions2025-01: 17 mentions2025-02: 11 mentions2025-03: 21 mentions2025-04: 13 mentions2025-05: 14 mentions2025-06: 6 mentions2025-07: 11 mentions2025-08: 8 mentions2025-09: 11 mentions2025-10: 7 mentions2025-11: 16 mentions2025-12: 17 mentions2026-01: 11 mentions2026-02: 13 mentions2026-03: 32 mentions2026-04: 22 mentions2026-05: 8 mentions2026-06: 2 mentions2026-07: 1 mentions2024-022026-07

Machine-classified coverage tone

87.7% positive-3.5 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cannabis policy reform discussions 16quarterly financials 16financial report 15solar hydrogen 14low-carbon hydrogen 14renewable h2 13earnings report 13electrolytic hydrogen 13

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-07-14 · trend and themes shown through 2026-07
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

AAWH

AWH

through 2026-04-29
Earnings releases 39Leadership changes 19Company announcements 3Asset acquisitions 1Business contracts 1
  1. Earnings releases

    today announced that it will hold a conference call on Wednesday, May 13, 2026, at 5:00 p.m. ET following the release of its first quarter 2026 financial results.

  2. Company announcements

    Ascend Wellness Holdings Inc. March 2, 2026 April 29, 2026 AS

  3. Leadership changes

    John Hartmann will no longer serve as Chief Executive Officer, and Mark Cassebaum has been terminated as Chief Financial Officer, effective immediately.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BTMD

Biote

through 2025-02-03
Earnings releases 10Leadership changes 4Lawsuits 1M&A 1
  1. Leadership changes

    Bret Christensen has been named Chief Executive Officer and Director, effective February 1.

  2. Earnings releases

    Revenue of $51.4 million Net income of $12.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.33

  3. Lawsuits

    Biote will repurchase all of the Class A common units of Biote Holdings, LLC (“Holdings Units”), shares of Class V common stock of the Company (“Class V Shares”)

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

USNA

USANA Health Sciences

through 2026-05-04
Earnings releases 20Company announcements 5M&A 1
  1. Earnings releases

    Analyists expect the company to announce earnings of $0.44 per share and revenue of $240.9880 million for the quarter.

  2. Company announcements

    Usana Health Sciences Inc (NYSE:USNA) has successfully rolled out an enhanced compensation plan designed to improve brand partner success and engagement.

  3. M&A

    SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) (the “Company,” “USANA”), today announced its acquisition of a 78.8% controlling ownership stake in Hiya Health Products, LLC (“Hiya”), a leading direct-to-consumer provider of high-quality children’s health & wellness products.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MRMD

MariMed Inc

through 2025-11-05
Earnings releases 14Company announcements 1Leadership changes 1
  1. Earnings releases

    MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2025.

  2. Leadership changes

    today announced the appointment of Mario Pinho to Chief Financial Officer (“CFO”), effective August 9, 2024.

  3. Company announcements

    For example, ongoing global supply chain issues with construction equipment and supplies has cost multistate operator MariMed Inc. (CSE: MRMD) (OTCQX: MRMD) months in delays at various expansion projects in multiple states.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NAII

Natural Alternatives International

through 2026-02-13
Earnings releases 36Leadership changes 2Company announcements 1
  1. Earnings releases

    today announced a net loss of $2.6 million , or $0.42 per diluted share, on net sales of $34.8 million for the second quarter of fiscal year 2026

  2. Leadership changes

    "I am pleased to announce Aaron Starr has been named vice president of CarnoSyn Brands," says Kenneth Wolf, president and chief operating officer, Natural Alternatives International.

  3. Company announcements

    Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII) today announced the expected May 2024 reopening of its state-of-the-art high-volume powder blending and packaging facility located in Carlsbad, CA, following a 7-month closure.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Medicinal Chemicals And Botanical Products Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary medicinal chemicals and botanical products news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

botanical ingredients market

3 sources63.9% extraction confidence
2022 extracted base$164.10B
2032 extracted forecast$331.90B
Implied source CAGR7.3%
numerous health and wellness benefitscritical factorsindustry's future trajectory

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Medicinal Chemicals And Botanical Products news pulse

28,410available Prism news records
Latest 12m volume-24.9%10421 vs 13883 records
Positive classified tone71.6%-1.1 pp vs prior four quarters
2024-01: 934 mentions2024-02: 758 mentions2024-03: 777 mentions2024-04: 781 mentions2024-05: 856 mentions2024-06: 785 mentions2024-07: 668 mentions2024-08: 702 mentions2024-09: 703 mentions2024-10: 821 mentions2024-11: 855 mentions2024-12: 621 mentions2025-01: 979 mentions2025-02: 2,081 mentions2025-03: 3,741 mentions2025-04: 1,095 mentions2025-05: 832 mentions2025-06: 551 mentions2025-07: 818 mentions2025-08: 1,758 mentions2025-09: 841 mentions2025-10: 878 mentions2025-11: 823 mentions2025-12: 746 mentions2026-01: 450 mentions2026-02: 1,040 mentions2026-03: 1,112 mentions2026-04: 1,354 mentions2026-05: 50 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching botanical, chemical, medicinal, ingredient. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

chemical plant explosions and hazardous material leaks
3,214
ethnobotany and traditional medicinal plant research
2,145
industrial accident investigations and reports
1,895
regulatory compliance in chemical industries
1,846
global chemical market trends and analysis
1,730
environmental contamination incidents
1,645

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

chemical safety assessments 1,918osha chemical standards 1,377chemical pricing 1,057plant explosion 938chemical accident 937bulk chemical suppliers 669commodity chemical sourcing 642cosmetic regulation 588

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

numerous health and wellness benefits

3 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

chemical plant explosions and hazardous material leaks

3,214 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,462 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

synthetic products can be perfect substitutes for organic products

3,049 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

-24.9% news volume

The latest 12 months contain 10,421 matched records versus 13,883 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

71.6% positive · -1.1pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 2833 (Medicinal Chemicals And Botanical Products). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Medicinal Chemicals And Botanical Products Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Biote has the widest attention-readiness rank gap

It ranks #4 by measured news attention (8.4%) and #2 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Biote in Companies Radar

MariMed Inc shows a price-operating divergence to inspect

Its displayed filing-revenue change is +31.6% while its available monthly-close return is -90.7%. The signs differ, but the two measures cover different windows and do not establish causality.

Open MariMed Inc in Companies Radar
Explanations

Attention measures coverage volume, not quality

AWH's 48.7% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open AWH in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open AWH's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 40/100 score.

Open AWH in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon